HIV Infections
Conditions
Keywords
HIV/AIDS, Mobile application, Digital Health
Brief summary
Adherence to antiretroviral therapy (ART) is crucial for treatment success in HIV+ patients. This study proposes the use of a smartphone application, specifically developed for this project, to monitor ART adherence and assess quality of life among HIV+ patients. The aim is to optimize long-term disease management through the early identification of comorbidities and clinical complications
Detailed description
Since the first cases were reported more than 35 years ago, 78 million people have been infected with HIV and 35 million have died from AIDS-related illnesses. Currently, the availability of TARV regimens associated with good tolerability and high levels of efficacy make it necessary to turn attention toward new standards of efficacy indicative of patients' mental and physical well-being. Indeed, health-related quality of life (HRQoL) is becoming increasingly preponderant as a therapeutic outcome. Despite TARV-related viroimmunologic success, people living with HIV (PLWH) continue to have lower HRQoL than the general population. Indeed, much evidence confirms the impact on quality of life not only of therapeutic treatments but also of social and relationship issues and comorbidities. Improving HRQoL is now, therefore, a primary goal for the care and support of PLWH. Evaluations of new treatments and interventions to improve care, therefore, require the measurement, in addition to clinical endpoints, of HRQoL using valid and reliable instruments. Therefore, the importance of PROs (Patient Reported Outcomes), which represent the description of the patient's own reported state of health, without any interpretation by clinicians or health care personnel, emerges in this area. In this way, the patient is directly involved in his or her own process of care. Adherence to TARV is essential for successful treatment and improved quality of life. Unfortunately, non-adherence to treatment is a common problem among HIV-infected patients. The Covid-19 emergence has significantly revolutionized the health care system leading to the implementation of new modes of care, including the use of technological tools to ensure remote medical care. The present study, targeting HIV-infected patients undergoing virological suppression, aims to use a smartphone application to facilitate continuity of care remotely, promoting adherence to therapy and thus the effectiveness of TARV, assessing the patient's quality of life and identifying possible comorbidities or other critical clinical
Interventions
Enrolled subjects will be asked to download the app for free from their smartphone store. Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age ≥ 18 years * HIV-infected patients * HIV plasma RNA values \< 50 copies/mL * Patients referred to the HIV outpatient clinic at the SC Infectious Diseases of the Azienda Alexandria Hospital * Patients on a stable antiretroviral regimen for at least 6 months * Patients who have the ability to download the application under study * Patients who have signed the informed consent
Exclusion criteria
* Newly diagnosed patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effective use of the mobile application | 6 months | Frequency of interaction with the mobile application |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to therapy | Everyday, through study completion (6 months) | Frequency of click in the mobile application |
| EuroQol five-dimensional questionnaire | Twice, at baseline and after 4 months | Quality of life assessment questionnaire |
| Pittsburgh Sleep Quality index | Twice, at baseline and after 4 months | Quality of sleep assessment questionnaire |
| Generalized Anxiety Disorder 7 | Twice, at baseline and after 4 months | Questionnaire for assessment of generalized anxiety state |
Countries
Italy